Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M J Prince

Showing results (61-70 of 75) with videos related to

Pageof 8
Sort By:
Diabetes, Obesity & Metabolism|May 2, 2015
Similar efficacy and safety of LY2963016 insulin glargine and insulin glargine (Lantus®) in patients with type 2 diabetes who were insulin-naïve or previously treated with insulin glargine: a randomized, double-blind controlled trial (the ELEMENT 2 study)J Rosenstock, P Hollander, A Bhargava, et al.
Diabetes, Obesity & Metabolism|May 15, 2015
Efficacy and safety of LY2963016 insulin glargine compared with insulin glargine (Lantus®) in patients with type 1 diabetes in a randomized controlled trial: the ELEMENT 1 studyT C Blevins, D Dahl, J Rosenstock, et al.
Diabetes, Obesity & Metabolism|February 7, 2015
Short-term administration of the glucagon receptor antagonist LY2409021 lowers blood glucose in healthy people and in those with type 2 diabetesR P Kelly, P Garhyan, E Raddad, et al.
Neuroepidemiology|October 22, 2008
The prevalence, correlates and impact of dementia in Cuba. A 10/66 group population-based surveyJ Llibre Rodríguez, A Valhuerdi, I I Sanchez, et al.
Social Psychiatry and Psychiatric Epidemiology|February 6, 2016
Ethnicity and cardiovascular health inequalities in people with severe mental illnesses: protocol for the E-CHASM studyJ Das-Munshi, M Ashworth, F Gaughran, et al.
Diabetic Medicine : a Journal of the British Diabetic Association|December 16, 2016
Type 2 diabetes mellitus in people with severe mental illness: inequalities by ethnicity and age. Cross-sectional analysis of 588 408 records from the UKJ Das-Munshi, M Ashworth, M E Dewey, et al.
Acta Psychiatrica Scandinavica|October 15, 2014
Antipsychotic exposure prior to acute myocardial infarction in patients with serious mental illnessS-I Wu, K-L Kao, S-C Chen, et al.
Diabetes, Obesity & Metabolism|October 6, 2015
Evaluation of immunogenicity of LY2963016 insulin glargine compared with Lantus® insulin glargine in patients with type 1 or type 2 diabetes mellitusL L Ilag, M A Deeg, T Costigan, et al.
The British Journal of Psychiatry : the Journal of Mental Science|October 26, 1999
Cross-cultural comparison of depressive symptoms in Europe does not support stereotypes of ageingJ R Copeland, A T Beekman, M E Dewey, et al.
The British Journal of Psychiatry : the Journal of Mental Science|October 26, 1999
Development of the EURO-D scale--a European, Union initiative to compare symptoms of depression in 14 European centresM J Prince, F Reischies, A T Beekman, et al.
Pageof 8

Showing results (61-70 of 75) with videos related to

Sort By:
Pageof 8
Diabetes, Obesity & Metabolism|May 2, 2015
Similar efficacy and safety of LY2963016 insulin glargine and insulin glargine (Lantus®) in patients with type 2 diabetes who were insulin-naïve or previously treated with insulin glargine: a randomized, double-blind controlled trial (the ELEMENT 2 study)J Rosenstock, P Hollander, A Bhargava, et al.
Diabetes, Obesity & Metabolism|May 15, 2015
Efficacy and safety of LY2963016 insulin glargine compared with insulin glargine (Lantus®) in patients with type 1 diabetes in a randomized controlled trial: the ELEMENT 1 studyT C Blevins, D Dahl, J Rosenstock, et al.
Diabetes, Obesity & Metabolism|February 7, 2015
Short-term administration of the glucagon receptor antagonist LY2409021 lowers blood glucose in healthy people and in those with type 2 diabetesR P Kelly, P Garhyan, E Raddad, et al.
Neuroepidemiology|October 22, 2008
The prevalence, correlates and impact of dementia in Cuba. A 10/66 group population-based surveyJ Llibre Rodríguez, A Valhuerdi, I I Sanchez, et al.
Social Psychiatry and Psychiatric Epidemiology|February 6, 2016
Ethnicity and cardiovascular health inequalities in people with severe mental illnesses: protocol for the E-CHASM studyJ Das-Munshi, M Ashworth, F Gaughran, et al.
Diabetic Medicine : a Journal of the British Diabetic Association|December 16, 2016
Type 2 diabetes mellitus in people with severe mental illness: inequalities by ethnicity and age. Cross-sectional analysis of 588 408 records from the UKJ Das-Munshi, M Ashworth, M E Dewey, et al.
Acta Psychiatrica Scandinavica|October 15, 2014
Antipsychotic exposure prior to acute myocardial infarction in patients with serious mental illnessS-I Wu, K-L Kao, S-C Chen, et al.
Diabetes, Obesity & Metabolism|October 6, 2015
Evaluation of immunogenicity of LY2963016 insulin glargine compared with Lantus® insulin glargine in patients with type 1 or type 2 diabetes mellitusL L Ilag, M A Deeg, T Costigan, et al.
The British Journal of Psychiatry : the Journal of Mental Science|October 26, 1999
Cross-cultural comparison of depressive symptoms in Europe does not support stereotypes of ageingJ R Copeland, A T Beekman, M E Dewey, et al.
The British Journal of Psychiatry : the Journal of Mental Science|October 26, 1999
Development of the EURO-D scale--a European, Union initiative to compare symptoms of depression in 14 European centresM J Prince, F Reischies, A T Beekman, et al.
Pageof 8